Business Context and Reporting Period
Company: Community Healthcare Trust Inc (CHCT)
Filing Type: Form 8-K (Current Report)
Date of Report: February 18, 2025
Reporting Period: Event-based report regarding the entry into a material definitive agreement on February 18, 2025.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the authorization of a new capital raising facility:
- ATM Program Cap: Up to $300 million in aggregate gross sales price for Common Stock.
- Compensation: Sales agents and forward sellers are entitled to commissions not exceeding 2.0% of the gross sales price.
Material Changes
The Company entered into a Third Amended and Restated Sales Agency Agreement, replacing the Second Amended and Restated Sales Agency Agreement dated November 2, 2022. Key changes include:
- New Counterparties: The agreement includes Piper Sandler & Co., Evercore Group L.L.C., Fifth Third Securities, Inc., Huntington Securities, Inc., Janney Montgomery Scott LLC, KeyBanc Capital Markets Inc., Regions Securities LLC, Truist Bank, and Truist Securities, Inc.
- Forward Sale Capability: The agreement explicitly allows for forward sale agreements where the Company may sell shares to Forward Purchasers, who then sell borrowed shares to the market.
- Settlement Options: The Company may elect to physically settle, cash settle, or net share settle forward sale agreements.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company has no obligation to sell any securities under the new agreement. Actual sales will depend on market conditions, trading price, and capital needs. The Company expects to physically settle forward sale agreements within two years but retains the option for cash or net share settlement, which could result in no proceeds or an obligation to pay cash/shares.
Risks and Contingencies:
- Issuer Status Change: The Company anticipates it will no longer qualify as a "well-known seasoned issuer" upon filing its 2024 Form 10-K. Consequently, it intends to file a Post-Effective Amendment No. 1 to its current Form S-3 and subsequently a new non-automatic shelf registration statement.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ due to market conditions and pre-sale conditions.
- Related Party Transactions: Sales agents and their affiliates may engage in other commercial dealings with the Company, receiving fees for such services.
Investor Verification Checklist
- Verify the effectiveness of the Post-Effective Amendment No. 1 to the Form S-3 (File No. 333-268115) and the subsequent filing of the new non-automatic shelf registration statement.
- Monitor the Company's 2024 Form 10-K to confirm the loss of "well-known seasoned issuer" status and its impact on future capital raising flexibility.
- Review future 8-K filings to determine if the Company elects to cash settle or net share settle any forward sale agreements, which would impact cash flow and share count differently than physical settlement.
- Track the actual volume of shares sold under the $300 million ATM program to assess dilution and capital deployment.